PRIMAXIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Primaxin, and when can generic versions of Primaxin launch?
Primaxin is a drug marketed by Merck and is included in three NDAs.
The generic ingredient in PRIMAXIN is cilastatin sodium; imipenem. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cilastatin sodium; imipenem profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PRIMAXIN?
- What are the global sales for PRIMAXIN?
- What is Average Wholesale Price for PRIMAXIN?
Summary for PRIMAXIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 2 |
Drug Prices: | Drug price information for PRIMAXIN |
What excipients (inactive ingredients) are in PRIMAXIN? | PRIMAXIN excipients list |
DailyMed Link: | PRIMAXIN at DailyMed |
Recent Clinical Trials for PRIMAXIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Merck Sharp & Dohme Corp. | Phase 1 |
Pfizer | Phase 3 |
AstraZeneca | Phase 3 |
Pharmacology for PRIMAXIN
Drug Class | Penem Antibacterial Renal Dehydropeptidase Inhibitor |
Mechanism of Action | Dipeptidase Inhibitors |
US Patents and Regulatory Information for PRIMAXIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | PRIMAXIN | cilastatin sodium; imipenem | INJECTABLE;INJECTION | 062756-001 | Jan 8, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-002 | Dec 14, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Merck | PRIMAXIN | cilastatin sodium; imipenem | INJECTABLE;INJECTION | 062756-002 | Jan 8, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-001 | Dec 14, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PRIMAXIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-001 | Dec 14, 1990 | ⤷ Sign Up | ⤷ Sign Up |
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAVENOUS | 050587-002 | Nov 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAVENOUS | 050587-001 | Nov 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-002 | Dec 14, 1990 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PRIMAXIN
See the table below for patents covering PRIMAXIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 792429 | ⤷ Sign Up | |
South Korea | 850000425 | ⤷ Sign Up | |
Singapore | 65484 | ⤷ Sign Up | |
Australia | 8697382 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PRIMAXIN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2666774 | CR 2020 00037 | Denmark | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
2666774 | 132020000000073 | Italy | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPZIONALMENTE IN FORMA DEL MONOIDRATO, IMIPENEM E CILASTATINA, OPZIONALMENTE NELLA FORMA DEL SALE SODICO(RECARBRIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1420, 20200217 |
2666774 | 20C1032 | France | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM OPTIONNELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE OPTIONNELLEMENT SOUS FORME DE SEL SODIQUE; REGISTRATION NO/DATE: EU/1/19/1420 20200217 |
2666774 | C202030035 | Spain | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPCIONALMENTE EN FORMA DE MONOHIDRATO E IMIPENEM Y CILASTATINA; NATIONAL AUTHORISATION NUMBER: EU/1/19/1420; DATE OF AUTHORISATION: 20200213; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1420; DATE OF FIRST AUTHORISATION IN EEA: 20200213 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |